Last reviewed · How we verify
Others except finerenone — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Others except finerenone (Others except finerenone) — Bayer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Others except finerenone TARGET | Others except finerenone | Bayer | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Others except finerenone CI watch — RSS
- Others except finerenone CI watch — Atom
- Others except finerenone CI watch — JSON
- Others except finerenone alone — RSS
Cite this brief
Drug Landscape (2026). Others except finerenone — Competitive Intelligence Brief. https://druglandscape.com/ci/others-except-finerenone. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab